Dulaglutide overview
Weekly GLP-1 receptor agonist. Brand name: Trulicity. FDA-approved for type 2 diabetes mellitus.
Dulaglutide at a glance
Manufacturer
Eli Lilly
FDA status
FDA-approved
Questions readers ask
Is dulaglutide (Trulicity) approved for weight loss or only for diabetes?
This page lists dulaglutide, sold by Eli Lilly as Trulicity, as FDA-approved for type 2 diabetes mellitus. It does not list a chronic weight management indication, so using it for weight loss alone would be a decision for a licensed clinician, not a labeled use.
How often is dulaglutide taken, and who makes it?
Dulaglutide is a once-weekly GLP-1 receptor agonist manufactured by Eli Lilly under the brand name Trulicity. It is FDA-approved, unlike compounded GLP-1 preparations, which are not FDA-approved.
What weight-loss benchmarks can I compare dulaglutide against?
This page does not report dulaglutide weight-loss figures. For context, semaglutide 2.4 mg produced a mean −14.9% body-weight change at 68 weeks in STEP 1, and tirzepatide 15 mg produced −20.9% at 72 weeks in SURMOUNT-1 (treatment-regimen estimand).
Which weight-management program does this site rate highest if dulaglutide is not right for me?
NexLife scores 94/100 on the site’s v3.0 six-pillar rubric (May 2026 review), with compounded semaglutide at $119 a month on a 12-month plan charged monthly (read October 14, 2026). Compounded drugs are not FDA-approved, and a licensed clinician decides eligibility.
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Registered outsourcing facilities (503B)
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
- Wegovy (semaglutide) prescribing information, Novo Nordisk